Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation
Recruitment status was Recruiting
The effect of haematopoietic growth factors on neutrophil recovery after allogeneic bone marrow transplantation is well recognized. Recent laboratory studies demonstrated that these cytokines may also modify T-cell and dendritic cell function, but whether the effect is strong enough to alter the risk of graft-versus-host disease (GvHD) is unclear.
The aim of this randomised study is to determine the effect of granulocyte colony-stimulating factor [G-CSF] (Neupogen; filgrastim) on the risk of acute GvHD after allogeneic bone marrow transplantation.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Randomized Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00207792
|Contact: Tarek Ben Othman, MD||98901456 ext firstname.lastname@example.org|
|Centre National de Greffe de Moelle Osseuse||Recruiting|
|Contact: Tarek Ben Othman, MD 98901456 ext 00216 email@example.com|
|Principal Investigator: Tarek Ben Othman, MD|
|Principal Investigator:||Tarek Ben Othman, MD||Centre National de Greffe de Moelle Osseuse|